Form 4: Elanco Animal Health CEO Acquires Deferred Stock Units

Elanco Animal Health's CEO, Jeffrey N. Simmons, acquired 228.8628 deferred stock units on December 13, 2024, which will convert to common stock or cash upon termination or at a future date.

Summary

• Jeffrey N. Simmons, the President, CEO, and Director of Elanco Animal Health Inc., acquired 228.8628 deferred stock units on December 13, 2024.
• These deferred stock units represent the right to receive one share of Elanco common stock or the cash equivalent.
• The units will settle in cash or shares of common stock following termination of employment or during a specified future year, as per the Executive Deferral and Stock Match Plan.
• Following this transaction, Mr. Simmons directly owns 4,762.9119 shares of Elanco common stock.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to executive compensation, which is generally viewed neutrally to slightly positive as it aligns executive interests with company performance.

Positives

• The acquisition of deferred stock units by the CEO could be seen as a positive sign of confidence in the company's future performance.

Future Outlook

The deferred stock units will convert to cash or shares of common stock following termination of employment or during a specified future year.

Industry Context

This is a routine filing related to executive compensation and is common in publicly traded companies. It reflects the company's compensation strategy and alignment of executive interests with shareholder value.

Comparison to Industry Standards

• Stock-based compensation, including deferred stock units, is a common practice among publicly traded companies, particularly for executive-level employees.
• Companies like Zoetis and IDEXX Laboratories also use similar compensation methods to align executive interests with company performance.
• The number of units granted and the vesting schedule are typical for executive compensation packages in the animal health industry.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns the CEO's interests with the company's performance.

Key Dates

Keywords

Elanco Animal Health, deferred stock units, CEO, Jeffrey N. Simmons, stock acquisition, executive compensation, insider trading